Search

Merck & Co Inc.

Suletud

SektorTervishoid

150.28 -1.31

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

150.06

Max

150.81

Põhinäitajad

By Trading Economics

Sissetulek

2.9B

-1.3B

Müük

321M

17B

P/E

Sektori keskmine

119.161

56.659

Aktsiakasum

-0.13

Dividenditootlus

2.24

Kasumimarginaal

-8.051

Töötajad

73,000

EBITDA

3.4B

1.4B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+3.03% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

2.24%

2.18%

Järgmine tulemuste avaldamine

29. okt 2026

Järgmine dividendimakse kuupäev

7. okt 2026

Järgmine aktsia dividendi kuupäev (ex-date)

15. sept 2026

Turustatistika

By TradingEconomics

Turukapital

57B

365B

Eelmine avamishind

151.59

Eelmine sulgemishind

150.28

Uudiste sentiment

By Acuity

44%

56%

135 / 339 Pingereas Healthcare

Merck & Co Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. sept 2026, 23:05 UTC

Merck & Co Inc shares are higher in after-market trading, despite no specific news. Broader market signals show mixed economic indicators and rising Treasury yields.

3. sept 2026, 23:05 UTC

Merck & Co Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid broader market gains.

2. sept 2026, 19:46 UTC

Social Media
News

Merck & Co Inc is rising following positive results from the ATLAS-UC Phase 3 trial, which met its primary endpoint of clinical significance.

1. sept 2026, 23:07 UTC

Merck & Co Inc. shares were roughly flat during after-market hours, with no specific company news identified amid broader market fluctuations driven by rising oil prices.

31. aug 2026, 23:16 UTC

Merck & Co Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by escalating geopolitical tensions and inflation concerns.

28. aug 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

27. aug 2026, 23:01 UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

26. aug 2026, 23:11 UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25. aug 2026, 23:06 UTC

Social Media

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

24. aug 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

21. aug 2026, 19:31 UTC

News
Social Media

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

20. aug 2026, 19:31 UTC

News
Social Media
Event

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

19. aug 2026, 23:41 UTC

Event
Social Media

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

17. aug 2026, 19:36 UTC

News

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

15. aug 2026, 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

14. aug 2026, 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

13. aug 2026, 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

12. aug 2026, 19:56 UTC

News

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

11. aug 2026, 19:36 UTC

News

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

10. aug 2026, 19:36 UTC

Social Media
News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7. aug 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6. aug 2026, 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5. aug 2026, 19:43 UTC

News
Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4. aug 2026, 23:26 UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3. aug 2026, 20:03 UTC

News
Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31. juuli 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30. juuli 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29. juuli 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28. juuli 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27. juuli 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

Võrdlus sarnastega

Hinnamuutus

Merck & Co Inc. Prognoos

Hinnasiht

By TipRanks

3.03% tõus

12 kuu keskmine prognoos

Keskmine 154.88 USD  3.03%

Kõrge 180 USD

Madal 105 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Merck & Co Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

13

Osta

4

Hoia

0

Müü

Sentiment

By Acuity

135 / 339 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat